当前位置:首页 - 行情中心 - 东宝生物(300239) - 财务分析 - 现金流量表

东宝生物

(300239)

  

流通市值:33.56亿  总市值:33.78亿
流通股本:5.90亿   总股本:5.94亿

现金流量表

报告期2025-06-302025-03-312024-12-312024-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金342,473,382.7131,526,570.42594,615,415.78451,006,507.36
  收到的税费返还3,132,961.8181,063.2311,522,722.378,887,094.2
  收到其他与经营活动有关的现金3,209,237.61,147,946.4123,100,671.1412,868,595.07
  经营活动现金流入小计348,815,582.11132,755,580.06629,238,809.29472,762,196.63
  购买商品、接受劳务支付的现金180,860,276.63117,980,427.27326,493,813.48269,766,497.34
  支付给职工以及为职工支付的现金80,142,356.8940,146,708.73157,723,585.69114,983,717.06
  支付的各项税费29,073,959.339,161,975.0551,165,757.1637,042,102.67
  支付其他与经营活动有关的现金8,446,484.612,999,452.2624,724,534.8521,697,857.48
  经营活动现金流出小计298,523,077.46170,288,563.31560,107,691.18443,490,174.55
  经营活动产生的现金流量净额50,292,504.65-37,532,983.2569,131,118.1129,272,022.08
二、投资活动产生的现金流量:
  收回投资收到的现金--1-
  处置固定资产、无形资产和其他长期资产收回的现金净额91,55532,00034,077,20034,059,315.53
  收到的其他与投资活动有关的现金1,951,938,996.77941,540,747.682,295,037,577.88627,834,191.38
  投资活动现金流入小计1,952,030,551.77941,572,747.682,329,114,778.88661,893,506.91
  购建固定资产、无形资产和其他长期资产支付的现金28,827,962.099,457,782.5377,166,502.5859,460,976.35
  投资支付的现金--232,000,000116,000,000
  支付其他与投资活动有关的现金1,949,000,000940,000,0002,286,000,000621,000,000
  投资活动现金流出小计1,977,827,962.09949,457,782.532,595,166,502.58796,460,976.35
  投资活动产生的现金流量净额-25,797,410.32-7,885,034.85-266,051,723.7-134,567,469.44
三、筹资活动产生的现金流量:
  取得借款收到的现金54,400,00040,000,0003,000,0003,000,000
  收到其他与筹资活动有关的现金113,104.02-2,389,603.71,843,790.25
  筹资活动现金流入小计54,513,104.0240,000,0005,389,603.74,843,790.25
  偿还债务支付的现金25,686,700-8,000,0008,000,000
  分配股利、利润或偿付利息支付的现金15,415,096.64358,713.1915,808,830.2115,803,143.3
  支付其他与筹资活动有关的现金56,114,846.3644,450,000--
  筹资活动现金流出小计97,216,64344,808,713.1923,808,830.2123,803,143.3
  筹资活动产生的现金流量净额-42,703,538.98-4,808,713.19-18,419,226.51-18,959,353.05
四、汇率变动对现金及现金等价物的影响-57,817.13-62,097.883,321.57-52,653.22
五、现金及现金等价物净增加额-18,266,261.78-50,288,829.17-215,336,510.53-124,307,453.63
  加:期初现金及现金等价物余额498,114,881.48498,114,881.48713,451,392.01713,451,392.01
  期末现金及现金等价物余额479,848,619.7447,826,052.31498,114,881.48589,143,938.38
补充资料:
  净利润36,967,123.15-91,264,128.64-
  资产减值准备2,791,532.1-2,791,007.48-
  固定资产和投资性房地产折旧43,312,666.55-79,015,347.29-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧43,312,666.55-79,015,347.29-
  无形资产摊销3,947,242.74-7,421,477.11-
  长期待摊费用摊销627,993.11-1,385,575.34-
  处置固定资产、无形资产和其他长期资产的损失310,270.68--1,470,574.28-
  固定资产报废损失4,006.27-878,498.01-
  财务费用1,121,054.55-385,286.79-
  投资损失1,566,045.78-3,743,341.08-
  递延所得税1,638,629.23-2,047,061.65-
  其中:递延所得税资产减少-1,277,685.07-631,099.1-
    递延所得税负债增加2,916,314.3-1,415,962.55-
  存货的减少-40,271,039.06--72,335,773.88-
  经营性应收项目的减少99,887,085.84--11,726,548.76-
  经营性应付项目的增加-100,528,958.26--37,617,231.3-
  其他-1,081,148.03-3,349,522.94-
  现金的期末余额479,848,619.7-498,114,881.48-
  减:现金的期初余额498,114,881.48-713,451,392.01-
  现金及现金等价物的净增加额-18,266,261.78--215,336,510.53-
公告日期2025-08-292025-04-242025-04-242024-10-28
审计意见(境内)标准无保留意见
TOP↑